/Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report

NEWS

Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report

Shanghai Stock Exchange

2025/12/20

Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report Securities code: 688098 Securities abbreviation: Shenlian Biotech

Listed company: Shenlian Biopharmaceutical (Shanghai) Co., Ltd.

Stock listing place: Shanghai Stock Exchange

Stock abbreviation: Shenlian Biotechnology

Stock code: 688098

Information disclosure obligor 1: Shanghai Shen Tai Lian Investment Partnership (Limited Partnership) Executive Affairs Partner: Wang Rui

Registered address: Room 305, Building 1, No. 48 Jiangchuan East Road, Minhang District, Shanghai

Information disclosure obligor 2: Yang Yufang

Mailing address: Shanghai

Information disclosure obligor 3: Yang Congzhou

Mailing address: Shanghai

Information disclosure obligor 4: Wang Dongliang

Mailing address: Zhengzhou City, Henan Province

Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report

Information disclosure obligor 5: Nie Dongsheng

Mailing address: Shanghai

Nature of changes in equity interests: This change in equity is due to a change in the executive partner of Information Disclosure Obligor 1, resulting in the termination of the concerted action relationship between Information Disclosure Obligor 1 and other Information Disclosure Obligors, and the proportion of the company's shares held is no longer consolidated. It does not involve changes in the number of company shares held by each party.

Signing date: December 19, 2025

Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report

Statement of Information Disclosure Obligor

The information disclosure obligor prepares this report in accordance with the Securities Law of the People's Republic of China (hereinafter referred to as the "Securities Law"), the Measures for the Administration of Acquisitions of Listed Companies (hereinafter referred to as the "Acquisition Measures"), the "Standard No. 15 on the Content and Format of Information Disclosure by Companies that Offer Securities to the Public - Report on Changes in Equity" (hereinafter referred to as the "Standard No. 15") and relevant laws and regulations.
The information disclosure obligor has obtained the necessary authorization and approval to sign this report, and its performance does not violate or conflict with any terms in the partnership agreement or internal rules of the information disclosure obligor.
In accordance with the provisions of the "Securities Law", "Acquisition Management Measures" and "Standard No. 15", this report has fully disclosed the changes in shares held by the information disclosure obligor in Shenlian Biopharmaceutical (Shanghai) Co., Ltd. As of the date of signing this report, except for the information disclosed in this report, the information disclosure obligor has not increased or decreased its equity shares in Shenlian Biopharmaceutical (Shanghai) Co., Ltd. through any other means.
This change in equity is based on the information stated in this report. Except for the information disclosure obligor, no other person has been entrusted or authorized to provide information not listed in this report or to provide any explanation or explanation for this report.
The information disclosure obligor promises that this report does not contain false records, misleading statements or major omissions, and assumes legal responsibility for its authenticity, accuracy and completeness.

Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report

1. Basic information of information disclosure obligors

Information disclosure obligor 1: Shanghai Shen Tai Lian Investment Partnership (Limited Partnership), its basic information is as follows:

Company Name Shanghai Shen Tai Lian Investment Partnership (Limited Partnership) Company Type Limited Partnership

Registered address: Room 305, Building 1, No. 48 Jiangchuan East Road, Minhang District, Shanghai Executive Affairs Partner Wang Rui

Unified social credit code 91310112332476216W

Business scope: industrial investment, investment management. [Projects that require approval according to law shall be

Business activities can only be carried out after approval by relevant departments] Business period 2015-03-31 to 2035-03-30 Investment amount 18.806922 million yuan

Information disclosure obligor 2: Yang Yufang, whose basic information is as follows: Name Yang Yufang

Gender female

Nationality China

Correspondence address Shanghai

Whether you have obtained the right of residence in other countries or regions? No

Information disclosure obligor 3: Yang Congzhou, his basic information is as follows: Name Yang Congzhou

Gender male

Nationality China

Correspondence address Shanghai

Whether you have obtained the right of residence in other countries or regions? No

Information disclosure obligor 4: Wang Dongliang, his basic information is as follows: Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report

Name Wang Dongliang

Gender male

Nationality China

Correspondence address Zhengzhou City, Henan Province

Whether you have obtained the right of residence in other countries or regions? No

Information disclosure obligor 5: Nie Dongsheng, his basic information is as follows:

Name Nie Dongsheng

Gender male

Nationality China

Correspondence address Shanghai

Whether you have obtained the right of residence in other countries or regions? No

2. Information about the main person in charge of the information disclosure obligor

As of the signing date of this report, the main persons in charge of Information Disclosure Obligor 1 are as follows:

Long-term residence Whether to acquire other countries or names Gender Position Nationality

The right of abode in the local area Wang Rui Male Executive Partner Shanghai, China No

The information disclosure obligor’s equity interests in other domestic or overseas listed companies reach or exceed 5% of the company’s issued shares

As of the date of signing this report, with the exception of the Company, no information disclosure obligor has any equity interests in other domestic or overseas listed companies reaching or exceeding 5% of the company's issued shares.

4. Information disclosure obligor’s instructions regarding persons acting in concert

Before this equity change, Yipu Consulting, one of the company's controlling shareholders and actual controllers, controlled by Mr. Nie Dongsheng, was the executive partner of Shen Tailian. Mr. Nie Dongsheng was the appointed representative of Yipu Consulting, the executive partner of Shen Tailian. Therefore, the controlling shareholder and actual controller Yang Yufang, Yang Congzhou, Wang Dongliang, and Nie Dongsheng formed a concerted action relationship with Shanghai Shen Tailian Investment Partnership (Limited Partnership). After this equity change, Shen Tailian is no longer controlled by Mr. Nie Dongsheng, and the concerted acting relationship between Shen Tailian and Nie Dongsheng, Yang Yufang, Yang Congzhou and Wang Dongliang is terminated.

Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report

Section 3 Purpose of Equity Change and Shareholding Plan

1. The purpose of this equity change

Because Mr. Nie Dongsheng, one of the company's controlling shareholders and actual controllers, is the company's chairman, presiding over the company's strategic planning and various important decisions; Shen Tailian, as the company's employee shareholding platform, involves the management of many shareholding employees, partners and their partnership shares. In order to further focus on the company's business development, while ensuring the efficient operation and management of Shen Tailian, the executive affairs partner of Shen Tailian was changed from Yipu Consulting to Mr. Wang Rui with the unanimous consent of all partners. Therefore, Shen Tailian is no longer under the control of Mr. Nie Dongsheng, and the relationship between Shen Tailian and Nie Dongsheng, Yang Yufang, Yang Congzhou and Wang Dongliang acting in concert is terminated.

2. Information disclosure obligor’s shareholding plan within the next 12 months

As of the signing date of this report, the information disclosure obligor has no clear plan to increase or decrease its holdings in the next 12 months. If the information disclosure obligor plans to increase or reduce its holdings of shares of listed companies in the future, it will strictly comply with the requirements of relevant laws and regulations and promptly perform relevant information disclosure obligations and related procedures.

Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report

Section 4 Equity Change Methods

1. Information disclosure obligors hold equity interests in listed companies

Before this equity change, the company's controlling shareholders and actual controllers Nie Dongsheng, Yang Yufang, Yang Congzhou, Wang Dongliang and Shen Tailian collectively held 147,086,817 shares of the company, accounting for 35.82% of the company's total share capital. After this equity change, the concerted action relationship between the company's controlling shareholders and actual controllers Nie Dongsheng, Yang Yufang, Yang Congzhou, Wang Dongliang and Shen Tailian was terminated, and the company's shares held by Shen Tailian were no longer consolidated with the company's controlling shareholders and actual controllers Nie Dongsheng, Yang Yufang, Yang Congzhou, and Wang Dongliang.

The specific changes are as follows:

Name of shareholders who held shares before this change. Name of shareholders who held shares after this change.

Percent of total share capital Number of shares per total share capital (shares) Number of shares (shares)

Ratio Ratio Company Controlling Shares

East, actual control

Nie Dongsheng, Yang 126,399,203 30.78% 126,399,203 30.78% Yufang, Yang Congzhou,

Wang Dongliang

Shen Tailian 20,687,614 5.04% 20,687,614 5.04%

The relationship between Shen Tailian and Nie Dongsheng, Yang Yufang, and Yang totaling 147,086,817 35.82% Congzhou and Wang Dongliang acting in concert ended

stop

2. Basic situation of this equity change

This change in equity is due to the change in the executive affairs partner of Shen Tailian. The concerted action relationship between Shen Tailian and the company's controlling shareholder and actual controller Nie Dongsheng, Yang Yufang, Yang Congzhou, and Wang Dongliang has been terminated. As a result, the company's shares held by Shen Tailian are no longer consolidated with the company's controlling shareholder and actual controller Nie Dongsheng, Yang Yufang, Yang Congzhou, and Wang Dongliang.

3. Restrictions on the rights of listed company shares held by information disclosure obligors

As of the signing date of this report, there are no rights in the shares of the listed company held by the information disclosure obligor. Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report

Interest restrictions, including but not limited to shares being pledged, frozen, etc.

4. The impact of this equity change on listed companies

After the termination of the concerted party relationship, the number of company shares directly and indirectly held by the company's controlling shareholders and actual controllers Nie Dongsheng, Yang Yufang, Yang Congzhou and Wang Dongliang has not changed. The termination of the concerted party relationship will not affect the status of Nie Dongsheng, Yang Yufang, Yang Congzhou and Wang Dongliang as the company's controlling shareholders and actual controllers, nor will it harm the interests of the listed company and other shareholders.

Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report

Section 5: Purchase and sale of shares of listed companies within the first six months

As of the six months before the date of signing this report, the information disclosure obligor has not purchased or sold the company's stocks.

Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report

Section 6 Other important matters

As of the signing date of this report, the information disclosure obligor has truthfully disclosed the information related to this equity change in accordance with relevant regulations. There is no other information that must be disclosed to avoid misunderstandings about the contents of the report, and there is no other major information that the China Securities Regulatory Commission or the stock exchange requires the information disclosure obligor to provide in accordance with the law but has not provided it.

Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report

Section 7 Documents for Inspection

1. Documents for reference

A copy of the business license of information disclosure obligor 1;
Identity documents of the principal person in charge of information disclosure obligor 1;
Identity documents of information disclosure obligor 2, information disclosure obligor 3, information disclosure obligor 4, and information disclosure obligor 5;
"Termination Agreement for Concerted Acting Relationship";
"Simplified Equity Change Report" signed by the information disclosure obligor.

2. Preparation location of documents for reference

Office of the Board of Directors of Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report

Section 8 Statement of Information Disclosure Obligor

The company promises that there are no false records, misleading statements or major omissions in this report, and assumes individual and joint legal responsibility for its authenticity, accuracy and completeness.

Information disclosure obligor 1: Shanghai Shen Tai Lian Investment Partnership (Limited Partnership) Executive Affairs Partner: Wang Rui Signature: _______________

Statement date: December 19, 2025 Statement of the Information Disclosure Obligor of Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report

I (and the organization I represent) promise that there are no false records, misleading statements or major omissions in this report, and bear individual and joint legal responsibility for its authenticity, accuracy and completeness.

Information disclosure obligor 2: Yang Yufang Signature: _______________

Statement date: December 19, 2025 Statement of the Information Disclosure Obligor of Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report

Information disclosure obligor 3: Yang Congzhou Signature: _______________

Statement date: December 19, 2025 Statement of the Information Disclosure Obligor of Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report

Information disclosure obligor 4: Wang Dongliang Signature: _______________

Statement date: December 19, 2025 Statement of the Information Disclosure Obligor of Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report

Information disclosure obligor 5: Nie Dongsheng Signature: _______________

Statement date: December 19, 2025 Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report

Attachment: Equity Change Report

Basic situation

Shenlian Biopharmaceutical (Shanghai) listed company

Listed company name Shanghai

Co., Ltd. location

Stock abbreviation Shenlian Biotechnology Stock code 688098

Shanghai Shen Tailian Investment Partnership Jiangchuan Enterprise (Limited Partnership), Minhang District, Shanghai No. 305, Building 1, No. 48 East Road

room

Yang Yufang Name of Shanghai Municipal Information Disclosure Obligor Information Disclosure Obligor

name place of registration

Yang Congzhou Shanghai

Wang Dongliang Zhengzhou City, Henan Province

Nie Dongsheng Shanghai City increased 

Decrease 

Number of shares owned

Unchanged  (Depends on whether there are persons acting in concert or not. Yes  No Variable change

Termination of relationship, number of shares

No more combined calculations)

The information disclosure obligor is the information disclosure obligor

No. No. 1 listed company Yes No Whether it is a listed company Yes NoMajor shareholder Actual controller

Centralized trading through stock exchanges □

Agreement transfer □

Administrative transfer or change of state-owned shares □

Transfer by indirect means □

Equity change method (can obtain new shares issued by listed companies □

Option) Execution of court ruling □

Inherit □

gift □

Others ☑ (Change of concerted action relationship)

Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report

Shen Tailian

Stock type: Unlimited tradable shares

Number of shares held: 20,687,614 shares

Shareholding ratio: 5.04%

Person with information disclosure obligation

The number of shares owned by Yang Yufang, Yang Congzhou, Wang Dongliang and Nie Dongsheng before the disclosure and the types of listed public stocks: unrestricted tradable shares

Proportion of issued shares of the company Number of shares held: 126,399,203 shares

Shareholding ratio: 30.78%

The above-mentioned information disclosure obligors hold a total of 147,086,817 shares of the company, accounting for 35.82% of the company's total share capital.

Shen Tailian

Stock type: Unlimited tradable shares

Number of shares held: 20,687,614 shares

Shareholding ratio: 5.04%

After this equity change,

Persons with information disclosure obligations have

Number of shares in which Yang Yufang, Yang Congzhou, Wang Dongliang and Nie Dongsheng are interested

Stock type: Unlimited tradable shares

and change ratio

Number of shares held: 126,399,203 shares

Shareholding ratio: 30.78%

The above-mentioned information disclosure obligors hold the company's stocks separately and will no longer be calculated together. Time of change: The relevant change registration time is December 19, 2025. Changes in listed companies: The executive partner of Shen Tailian changes, the time and manner of the concerted action relationship between Shen Tailian and the company's controlling shareholders and actual controllers Nie Dongsheng, Yang Yufang, Yang Congzhou, and Wang Dongliang changes in the company's equity shares, resulting in the relevant interests no longer being combined, and the number of shares owned by both parties has not changed. Has funding been fully disclosed? Yes□ No□ Not applicable Source of funding

The person with the information disclosure obligation is

Yes□ No√

Is it planned to do so in the next 12 months?

There is no plan at the moment. If we increase/reduce our holdings, we will continue to increase our holdings in a timely manner in accordance with the requirements of relevant laws and regulations.

The review process and information disclosure obligations of the information disclosure obligor are

Were you in two countries in the previous 6 months?

Buy and sell the listing on the secondary market Yes□ No√

company stock

If it involves the reduction of shares held by the controlling shareholder or actual controller of a listed company, the information disclosure obligor shall also explain the following:

Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report

Whether the controlling shareholder or actual controller exists when reducing its holdings

Not applicable to issues that infringe on the rights and interests of listed companies and shareholders

Whether the controlling shareholder or actual controller has not paid off its inapplicable liabilities to the company when reducing its holdings, has not released the guarantee provided by the company for its liabilities, or has other circumstances that harm the company's interests.

Whether this equity change is not applicable requires approval

N/A Approved

(There is no text below) Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report (This page has no text, it is the signature page of "Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report Attachment")

Information disclosure obligor 1: Shanghai Shen Tai Lian Investment Partnership (Limited Partnership) Executive Affairs Partner: Wang Rui Signature: _______________

Statement date: December 19, 2025 Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report (This page has no text, it is the signature page of "Shenlian Biopharmaceutical (Shanghai) Co., Ltd. Simplified Equity Change Report Schedule")

Information disclosure obligor 2: Yang Yufang Signature: _______________

Information disclosure obligor 3: Yang Congzhou Signature: _______________

Information disclosure obligor 4: Wang Dongliang Signature: _______________

Information disclosure obligor 5: Nie Dongsheng Signature: _______________

Statement date: December 19, 2025